SCHEMBL1937258

SCHEMBL1937258

COc1nc(N[C@H]2CC[C@H](N(C(=O)O)C(C)(C)C)CC2)ccc1C#N

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.37
IKBKE Q14164 4/20 0.36
CCNK O75909 4/20 0.36
CCNA2 P20248 4/20 0.36
CDK2 P24941 4/20 0.36
CDK12 Q9NYV4 4/20 0.36
CCR6 P51684 2/20 0.35
IDH1 O75874 2/20 0.34
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CSNK2A1 P68400 1/20 0.33
CTSK P43235 1/20 0.33
TBK1 Q9UHD2 3/20 0.33
HCAR3 P49019 1/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
JAK3 P52333 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1937259 1.00 GAA (0.37) GAAIKBKECCNKCCNA2CDK2
SCHEMBL1935663 0.89 MAPK8 (0.37) GAACCNKCCNA2CDK2CDK12
SCHEMBL1935664 0.89 MAPK8 (0.37) GAACCNKCCNA2CDK2CDK12
SCHEMBL1936697 0.85 GPR65 (0.38) CCNKCCNA2CDK2CDK12CCR6
SCHEMBL1936695 0.85 GPR65 (0.38) CCNKCCNA2CDK2CDK12CCR6
SCHEMBL1935846 0.82 ROCK2 (0.43)
SCHEMBL1935844 0.82 ROCK2 (0.43)
SCHEMBL15739724 0.82 KDM4E (0.46) GAAIKBKECDK2CCR6IDH1
SCHEMBL3629374 0.82 GAA (0.44) GAAIKBKECCNKCDK12CCR6
SCHEMBL3629373 0.82 GAA (0.44) GAAIKBKECCNKCDK12CCR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166161-A1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS ASTELLAS PHARMA INC. (JP) 2011-07-07 US disclosed
EP-2331507-A2 HETEROCYCLIC CARBOXAMIDE COMPOUNDS Astellas Pharma Inc. (JP) 2011-06-15 EP disclosed
WO-2010032875-A2 HETEROCYCLIC CARBOXAMIDE COMPOUNDS ASTELLAS PHARMA INC. (JP) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166161-A1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS ROCK1, ROCK2, RHOT2 GAA 1469/4885IKBKE 277/4885CCNK 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.